Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
Body unavailable. Use the original source.
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.